Kiromic BioPharma (formerly known as Kiromic) is a target discovery and gene editing company focusing on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. It develops an allogeneic chimeric antigen receptor (CAR) cell product candidate against cancer, a checkpoint inhibitor for solid tumors, as well as oral healthcare products. The company also offers DIAMOND AI (Kiromic Diamond Artificial Intelligence), a multi-purpose computational platform that can identify cancer immunological targets for T-Cells and B-Cells.
|HQ||Houston, TX, US||Map|
Net income (FY, 2020)
EBIT (FY, 2020)
Market capitalization (29-Jul-2021)
Closing stock price (29-Jul-2021)
Kiromic Biopharma has 86 Twitter Followers. The number of followers has increased 6.5% month over month and increased 8.9% quarter over quarter
When was Kiromic Biopharma founded?
Kiromic Biopharma was founded in 2012.
Who are Kiromic Biopharma key executives?
Kiromic Biopharma's key executives are Maurizio Chiriva-Internati, Gianluca Rotino and Scott Dahlbeck.
How many employees does Kiromic Biopharma have?
Kiromic Biopharma has 13 employees.
Who are Kiromic Biopharma competitors?
Competitors of Kiromic Biopharma include Xilio Therapeutics, RAPT Therapeutics and Alligator Bioscience.
Where is Kiromic Biopharma headquarters?
Kiromic Biopharma headquarters is located at 7707 Fannin St Suite 140, Houston.
Where are Kiromic Biopharma offices?
Kiromic Biopharma has an office in Houston.
How many offices does Kiromic Biopharma have?
Kiromic Biopharma has 1 office.
Receive alerts for 300+ data fields across thousands of companies